Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep activates interferon (IFN) signalling

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Dec 28, 2022 12:05pm

160 Views

Post# 35193696

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates interferon (IFN) signalling

CAR T - Next Generation CAR & T Cell Therapies Feb 27 - March 2, 2023.

This event is in San Diego, and a more likely venue.

It would simplify matters if the company would issue an update. Que sera sera.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023